VEGF (121 a.a.) Mouse
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
Recombinant Mouse VEGF-121 is a truncated version of Murine VEGF-165.
The VEGF-121 is purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Vascular Endothelial Growth Factor (VEGF) is a signal protein that stimulates the formation of blood vessels. It plays a crucial role in both vasculogenesis (the formation of the circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). VEGF is essential for the growth and development of tissues and organs, as well as for wound healing and the formation of granulation tissue.
VEGF exists in several isoforms, which are produced through alternative splicing of mRNA. The most common isoforms are VEGF121, VEGF165, VEGF189, and VEGF206. These isoforms differ in their molecular weight and their ability to bind to cell surface receptors and the extracellular matrix.
The VEGF121 isoform, specifically, is a truncated version of the more common VEGF165. It consists of 121 amino acids and lacks the heparin-binding domain present in the longer isoforms. This makes VEGF121 more diffusible and less likely to be sequestered by the extracellular matrix .
Recombinant VEGF121 (Mouse) is typically produced in bacterial systems such as E. coli. The recombinant protein is expressed as a homodimer, non-glycosylated polypeptide chain containing 121 amino acids, with a molecular mass of approximately 28.4 kDa . The purification process involves proprietary chromatographic techniques to ensure high purity and bioactivity .
VEGF121 retains the ability to bind to VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This binding activates signaling pathways that promote endothelial cell proliferation, migration, and new blood vessel formation. VEGF121 is particularly important in pathological conditions where angiogenesis is required, such as in tumor growth, diabetic retinopathy, and rheumatoid arthritis.
Recombinant VEGF121 has been studied for its potential therapeutic applications. For instance, it has been shown to attenuate autoantibody-induced features of pre-eclampsia in pregnant mice. Pre-eclampsia is a serious hypertensive disorder of pregnancy characterized by excessive production of a soluble form of the VEGF receptor-1 (sFlt-1). Infusion of recombinant VEGF121 in pregnant mice significantly reduced hypertension, proteinuria, and glomerular damage induced by autoantibodies .
